IBD is an innovative SME, a manufacturer of biomedical devices conceived in London and founded in Italy in 2014.
Led by a team with more than 10 years of experience in medical device design, IBD has so far raised over € 1 million in business angel funding and grants. p >
It is now facing a new round of funding and is constantly looking for investors who believe in the values and goals that drive IBD.
IBD considers the Reverse Innovation of medical devices the key to making quality health care accessible to the whole world .
Our mission is tackling health problems through the application of the principles of reverse innovation.
We observe the technological limitations and clinical needs existing in the global healthcare environment to create the best solution in terms of safety and efficacy , optimization of costs, and usability .
The MyDial technological concept has been formulated.
In May 2014 Corrado Ghidini and Andrea Visotti founded the Start up IBD Srl and opened an R&D laboratory in Bologna (Italy).
The first prototype of MyDial was developed using a PC-controlled data acquisition platform.
IBD obtained the EN ISO 13485 and EN ISO 9001 Certifications from TUV Sud
The second prototype of MyDial, based on a first version of PC-independent embedded electronics, was developed and tested in the laboratory.
IBD prototyped the Manifold, improved the ultrafiltration control and started activities to obtain the CE certification of Dial-IT
Certificate 854722 delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
IBD obtained non-repayable loan of 100k€ from the Emilia-Romagna Region.
The third protype of MyDial has been tested and validated in vitro.
Industrialization and Certification process Industrialization of the whole MyDial system and CE certification process begins, for hospital use.
Seals of Excellence Horizon 2020 Two more seals assigned by European Commission: 867214 – 888419
Certificate issued by the European Commission, as managing body of Horizon 2020, of the EU Framework Program for Research and Innovation 2014-2020 for proposal 970477.
To respond to the pandemic, engineers create the first prototype of the Biorespira lung ventilator in just 5 weeks.
Partnership with SECO GROUP, a leading company in the hi-tech sector, specialized in IT miniaturization, supported by FII Tech Growth managed by the Italian Investment Fund SGR, for the industrialization of Biorespira.
IBD has launched a successful crowdfunding campaign, called #LetThemBreathe, to support Biorespira’s development activities.
During the COVID-19 pandemic, in an effort to help alleviate the emergency and shocked by the scarce presence of ventilator manufacturers in Italy, the team decided to develop a sub-intensive care ventilator with high flow and mixing of oxygen.
Biorespira has been tested and validated and CE certified by KIWA Cermet Italia.
The MyDial technological concept has been formulated.
In May 2014 Corrado Ghidini and Andrea Visotti founded the Start up IBD Srl and opened an R&D laboratory in Bologna (Italy).
The first prototype of MyDial was developed using a PC-controlled data acquisition platform.
IBD obtained the EN ISO 13485 and EN ISO 9001 Certifications from TUV Sud
The second prototype of MyDial, based on a first version of PC-independent embedded electronics, was developed and tested in the laboratory.
IBD prototyped the Manifold, improved the ultrafiltration control and started activities to obtain the CE certification of Dial-IT
Certificate 854722 delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
IBD obtained non-repayable loan of 100k€ from the Emilia-Romagna Region.
The third protype of MyDial has been tested and validated in vitro.
Industrialization and Certification process Industrialization of the whole MyDial system and CE certification process begins, for hospital use.
Seals of Excellence Horizon 2020 Two more seals assigned by European Commission: 867214 – 888419
Certificate issued by the European Commission, as managing body of Horizon 2020, of the EU Framework Program for Research and Innovation 2014-2020 for proposal 970477.
To respond to the pandemic, engineers create the first prototype of the Biorespira lung ventilator in just 5 weeks.
Partnership with SECO GROUP, a leading company in the hi-tech sector, specialized in IT miniaturization, supported by FII Tech Growth managed by the Italian Investment Fund SGR, for the industrialization of Biorespira.
IBD has launched a successful crowdfunding campaign, called #LetThemBreathe, to support Biorespira’s development activities.
During the COVID-19 pandemic, in an effort to help alleviate the emergency and shocked by the scarce presence of ventilator manufacturers in Italy, the team decided to develop a sub-intensive care ventilator with high flow and mixing of oxygen.
Biorespira has been tested and validated and CE certified by KIWA Cermet Italia.
The MyDial technological concept has been formulated.
In May 2014 Corrado Ghidini and Andrea Visotti founded the Start up IBD Srl and opened an R&D laboratory in Bologna (Italy).
The first prototype of MyDial was developed using a PC-controlled data acquisition platform.
IBD obtained the EN ISO 13485 and EN ISO 9001 Certifications from TUV Sud
The second prototype of MyDial, based on a first version of PC-independent embedded electronics, was developed and tested in the laboratory.
IBD prototyped the Manifold, improved the ultrafiltration control and started activities to obtain the CE certification of Dial-IT
Certificate 854722 delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
IBD obtained non-repayable loan of 100k€ from the Emilia-Romagna Region.
The third protype of MyDial has been tested and validated in vitro.
Industrialization and Certification process Industrialization of the whole MyDial system and CE certification process begins, for hospital use.
Seals of Excellence Horizon 2020 Two more seals assigned by European Commission: 867214 – 888419
Certificate issued by the European Commission, as managing body of Horizon 2020, of the EU Framework Program for Research and Innovation 2014-2020 for proposal 970477.
To respond to the pandemic, engineers create the first prototype of the Biorespira lung ventilator in just 5 weeks.
Partnership with SECO GROUP, a leading company in the hi-tech sector, specialized in IT miniaturization, supported by FII Tech Growth managed by the Italian Investment Fund SGR, for the industrialization of Biorespira.
IBD has launched a successful crowdfunding campaign, called #LetThemBreathe, to support Biorespira’s development activities.
During the COVID-19 pandemic, in an effort to help alleviate the emergency and shocked by the scarce presence of ventilator manufacturers in Italy, the team decided to develop a sub-intensive care ventilator with high flow and mixing of oxygen.
Biorespira has been tested and validated and CE certified by KIWA Cermet Italia.
IBD ITALIAN BIOMEDICAL DEVICES SRL
Via Tasso 14 – 46043 Castiglione delle Stiviere Mantova – Italia | P.IVA 02433320203
© IBD biomed All rights reserved.
I declare that I am aware that the contents of this site are intended for healthcare professionals, in accordance with the provisions of the Ministry of Health regarding health advertising relating to medical devices, in vitro diagnostic medical devices and medical-surgical devices. I also acknowledge that the description of the products is for informational purposes only and is not intended to promote them.